{"groups":[{"description":"Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.\n\nBortezomib: AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).\n\nMelphalan: AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\\^2/day IV over 30 minutes.\n\nFludarabine: Days -6,-5,-4,-3 Fludarabine 30 mg/m\\^2/day IV\n\nAllogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with granulocyte colony-stimulating factor (GCSF) mobilization and infused fresh to recipients. Allogeneic donor stem cells may be cryopreserved if they cannot be infused","id":"FG000","title":"A: Allogeneic Stem Cell Transplant"},{"description":"Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.\n\nBortezomib: AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).\n\nMelphalan: AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\\^2/day IV over 30 minutes.\n\nAutologous Stem Cell Transplant: Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (G-CSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.","id":"FG001","title":"B: Autologous Stem Cell Transplant"},{"description":"Group B Expansion on Bortezomib Maintenance: Autologous Only.\n\nBortezomib: AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).\n\nMelphalan: AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\\^2/day IV over 30 minutes.\n\nAutologous Stem Cell Transplant: Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (G-CSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.","id":"FG002","title":"BE: Group B Expansion"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"}],"type":"Did not start study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Insurance issues"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}],"type":"Transplant eligibility issues"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}],"type":"Not evaluable at time of analysis"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"51"},{"groupId":"FG002","numSubjects":"39"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"37"},{"groupId":"FG002","numSubjects":"38"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants were enrolled at Moffitt Cancer Center August 2009 through April 2015."}